chapter 17 substance abuse copyright © 2014 by mosby, an imprint of elsevier inc

45
Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Upload: hilary-harrington

Post on 19-Dec-2015

230 views

Category:

Documents


2 download

TRANSCRIPT

Page 1: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Chapter 17

Substance Abuse

Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 2: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Physical dependence Psychologic dependence Habituation Addiction

Substance Abuse: Leads to Dependence

2Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 3: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Opioids Stimulants

Methamphetamine Methylenedioxymethamphetamine (MDMA,

“ecstasy”) Cocaine

Depressants Benzodiazepines Barbiturates Marijuana

Commonly Abused Substances

3Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 4: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Alcohol Anabolic steroids Dextromethorphan Lysergic acid diethylamide (LSD) Nicotine Phencyclidine (PCP)

Commonly Abused Substances

4Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 5: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Opioids

opium heroin

(diacetylmorphine) morphine codeine hydromorphone

hydrocodone meperidine oxycodone propoxyphene methadone

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 5

Page 6: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Also known as narcotics Opium and heroin are Schedule I Most others are Schedule II because of their

high potential for abuse Often abused because of their ability to

produce euphoria

Opioids (cont’d)

6Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 7: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Produce analgesia, drowsiness, euphoria, tranquility, other mood alterations

Affect areas outside the central nervous system (CNS) Skin, GI tract, GU tract

Normally used to: Relieve pain, reduce cough, relieve diarrhea, and

induce anesthesia

Opioids (cont’d)

7Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 8: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Heroin Injected (“mainlining” or “skin popping”) Sniffed (“snorted”) Smoked

Causes a brief “rush,” followed by a few hours of a relaxed, contented state

Large doses can stop respirations Methadone

Opioids (cont’d)

8Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 9: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Central nervous system Diuresis Miosis Convulsions Nausea, vomiting Respiratory depression

Opioids: Adverse Effects

9Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 10: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Non–central nervous system Hypotension Constipation Urinary retention Flushing of the face, neck, and upper thorax Sweating, urticaria, and pruritus

Opioids: Adverse Effects (cont’d)

10Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 11: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Peak period: 1 to 3 days Duration: 5 to 7 days Signs

Drug seeking, mydriasis, diaphoresis, rhinorrhea, lacrimation, diarrhea, elevated BP and pulse

Symptoms Intense desire for drug, muscle cramps, arthralgia,

anxiety, nausea, vomiting, malaise

Opioid Drug Withdrawal

11Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 12: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Block opioid receptors so that use of opioid drugs does not produce euphoria

Naltrexone—an opioid antagonist Vivitrol—injectable form of naltrexone Naloxone combined with buprenorphine

(Subutrex) or used alone (Suboxone)

Opioid Drug Withdrawal: Treatment

12Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 13: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Elevation of mood Reduction of fatigue Increased alertness Invigorated aggressiveness

Stimulants

13Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 14: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Amphetamines Methamphetamine MDMA (“ecstasy”)

cocaine methylphenidate (Ritalin)

Stimulants

14Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 15: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Stronger effects than other amphetamines Pill form Powder form: snorted or injected Crystallized form:

Also known as “ice,” “crystal,” “glass,” “crystal meth” Smokable More powerful Sales of over-the-counter (OTC) pseudoephedrine

are now regulated

Methamphetamine

15Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 16: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Usually prepared in secret home laboratories More calming effects than other amphetamine

drugs Usually taken by pill “Raves”

Methylenedioxymethamphetamine (MDMA, “ecstasy,” or “E”)

16Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 17: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

From the leaves of the coca plant Snorted or injected intravenously Highly addictive—physical and psychologic

dependence Powdered form

Also called “dust,” “coke,” “snow,” “flake,” “blow,” “girl”

Crystallized form (smoked) Also called “crack,” “freebase rocks,” “rock”

Cocaine

17Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 18: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Stimulants: Adverse Effects

CNS Restlessness Syncope (fainting) Tremor Hyperactive reflexes Talkativeness Irritability Insomnia Fever Euphoria

Confusion Aggression Increased libido Anxiety Delirium Paranoid

hallucinations Suicidal or homicidal

tendencies

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 18

Page 19: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Cardiovascular Headache Chilliness Pallor or flushing Palpitations Tachycardia Cardiac dysrhythmias Anginal pain Hypertension or hypotension Circulatory collapse

Stimulants: Adverse Effects

19Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 20: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Stimulants: Adverse Effects

Gastronintestinal Dry mouth Metallic taste Anorexia Nausea Vomiting Diarrhea Abdominal cramps

Fatal hyperthermia

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 20

Page 21: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Death results from: Convulsions Coma Cerebral hemorrhage

May occur during periods of intoxication or withdrawal

Stimulant Overdose

21Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 22: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Peak period: 1 to 3 days Duration: 5 to 7 days Signs

Social withdrawal, psychomotor retardation, hypersomnia, hyperphagia

Symptoms Depression, suicidal thoughts and behavior,

paranoid delusions No specific pharmacologic treatments

Stimulant Withdrawal

22Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 23: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Drugs that relieve anxiety, irritability, and tension

Used to treat seizure disorders and induce anesthesia

Two main pharmacologic classes: Benzodiazepines (flunitrazepam) Barbiturates

Marijuana (“pot,” “grass,” “weed”)

Depressants

23Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 24: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

CNS Drowsiness, sedation, loss of coordination,

dizziness, blurred vision, headaches, and paradoxical reactions

Gastronintestinal Nausea, vomiting, constipation, dry mouth, and

abdominal cramping Pruritus and skin rash “Amotivational” syndrome

Depressants: Adverse Effects

24Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 25: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Peak period 2 to 4 days for short-acting drugs 4 to 7 days for long-acting drugs

Duration 4 to 7 days for short-acting drugs 7 to 12 days for long-acting drugs

Signs Increased psychomotor activity; agitation;

hyperthermia; diaphoresis; delirium; convulsions; elevated BP, pulse rate, and temperature; others

Depressants Withdrawal

25Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 26: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Symptoms Anxiety, depression, euphoria, incoherent thoughts,

hostility, grandiosity, disorientation, hallucinations, suicidal thoughts

Treatment involves tapering of the drug over a course of a 7 to 10 or 10 to 14 days

Depressants Withdrawal (cont’d)

26Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 27: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Classroom Response Question

Which drug will the nurse anticipate administering to a patient experiencing benzodiazepine overdose?

A. flumazenil

B. naltrexone

C. Vivitrol

D. flunitrazepam

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 27

Page 28: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

More accurately known as ethanol (ETOH) Causes CNS depression by dissolving in lipid

membranes in the CNS Few legitimate uses of ethanol and alcoholic

beverages Used as a solvent for many drugs

Alcohol (Ethanol)

28Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 29: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

CNS depression Respiratory stimulation or depression Vasodilation, producing warm, flushed skin Increased sweating Diuretic effects

Ethanol: Drug Effects

29Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 30: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Nutritional and vitamin deficiencies (especially B vitamins) Wernicke’s encephalopathy Korsakoff’s psychosis Polyneuritis Nicotinic acid deficiency encephalopathy

Seizures Alcoholic hepatitis, progressing to cirrhosis Cardiomyopathy

Effects of Chronic Ethanol Ingestion

30Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 31: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Fetal alcohol syndrome (FAS) Craniofacial abnormalities CNS dysfunction Prenatal and postnatal growth retardation

Effects of Chronic Ethanol Ingestion (cont’d)

31Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 32: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Signs and symptoms Elevated blood pressure, pulse rate, and

temperature Insomnia Tremors Agitation

Classified as mild, moderate, and severe

Ethanol Withdrawal

32Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 33: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Classroom Response Question

A patient with a diagnosis of delirium tremens is admitted to the acute care facility. Which finding does the nurse expect upon assessment of the patient?

A. Hyperthermia

B. Hypotension

C. Bradycardia

D. Somnulence

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 33

Page 34: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Benzodiazepines are the treatment of choice diazepam (Valium), lorazepam (Ativan), or

chlordiazepoxide (Korsakoff’s psychosis) Dosage and frequency depend on severity

For severe withdrawal, monitoring in an intensive care unit is recommended

Ethanol Withdrawal Treatment

34Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 35: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

disulfiram (Antabuse) Acetaldehyde syndrome

naltrexone acamprosate (Campral)

Newest treatment Counseling

Individual Alcoholics Anonymous

Treatment for Alcoholism

35Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 36: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Classroom Response Question

Which statement does the nurse include when teaching a patient about disulfiram (Antabuse) therapy?

A.“Disulfiram (Antabuse) will cure your alcoholism if you take it as directed.”

B.“If you drink alcohol after taking disulfiram (Antabuse), your blood pressure will get very high.”

C.“You cannot drink alcohol for at least 3 or 4 days after taking disulfiram (Antabuse).”

D.“If you miss a dose of disulfiram (Antabuse), double the dose the next time it is due.”

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 36

Page 37: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Many smoke to “calm nerves” Releases epinephrine, which creates

physiologic stress rather than relaxation Tolerance develops Physical and psychologic dependency Withdrawal symptoms occur if stopped No therapeutic uses 200 known poisons present in cigarette smoke

Nicotine

37Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 38: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Transient stimulation of autonomic ganglia Followed by more persistent depression of all

autonomic ganglia CNS and respiratory stimulation, followed by

CNS depression Increased heart rate and BP Increased bowel activity

Nicotine:Drug Effects

38Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 39: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Manifested by cigarette craving Irritability, restlessness, decreased heart rate and BP

Cardiac symptoms resolve in 3 to 4 weeks, but cigarette craving may persist for months or years

Nicotine Withdrawal

39Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 40: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Treatments provide nicotine without the carcinogens in tobacco : Nicotine transdermal system (patch) Nicotine polacrilex (gum) Inhalers Nasal spray

Nicotine Withdrawal Treatment

40Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 41: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

bupropion (Zyban) may be prescribed to aid in smoking cessation First nicotine-free prescription medicine to treat

nicotine dependence varenicline (Chantix)

Stimulates nicotine receptors

Nicotine Withdrawal Treatment

41Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 42: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Classroom Response Question

The nurse is explaining the differences between transdermal nicotine and nicotine gum programs. Which statement by the nurse is correct?

A. “The nicotine patch will give you quick relief from cravings.”

B. “Chewing the gum rapidly will release an immediate dose of nicotine.”

C. “It seems that patients have better treatment compliance with the gum than the patch.”

D. “The dose of nicotine in the gum is approximately twice the dose the average smoker receives in one cigarette.”

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 42

Page 43: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Assessments should include nonjudgmental and open-ended questions about substance abuse

Be observant for clues to substance abuse so as to avoid withdrawal symptoms

The most dangerous substances in terms of withdrawal are CNS depressants such as barbiturates, benzodiazepines, and alcohol

Establish therapeutic rapport, and use empathy toward the patient

Nursing Implications

43Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 44: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Assessment tools for substance abuse CAGE Alcoholism Screening Test Adapted to

Include Drugs (CAGE-AID) Substance Abuse Subtle Screening Inventory

(SASSI) Michigan Alcoholism Screening Test Geriatric

version (MAST-G) Problem Oriented Screening Instrument for

Teenagers (POSIT)

Nursing Implications (cont’d)

44Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 45: Chapter 17 Substance Abuse Copyright © 2014 by Mosby, an imprint of Elsevier Inc

Patient safety is of utmost importance at all times during patient care but especially when the patient is experiencing the signs and symptoms of withdrawal

Provide monitoring and support as needed throughout the withdrawal process

Educate the patient and family members or significant others about the recovery process

Emphasize that recovery is lifelong

Nursing Implications (cont’d)

45Copyright © 2014 by Mosby, an imprint of Elsevier Inc.